AFM
LUMO

Anson Funds Management’s Lumos Pharma, Inc. Common Stock LUMO Stock Holding History

Anson Funds Management’s Portfolio LUMO Stock Details LUMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-31,362
Closed -$429K – 54
2018
Q4 		$429K Buy
+31,362
New +$552K 0.25% 22

Other funds holding LUMO

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $26.7B AUM 36.4% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $43.4B AUM 51.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
OAM
Oxford Asset Management Oxford, United Kingdom $232M AUM 31% 1-Year Est. Return

Anson Funds Management's LUMO Position: Q1 2019 in Review

Anson Funds Management sold out of Lumos Pharma, Inc. Common Stock (LUMO) in Q1 2019, closing a stake of 31,362 shares — an estimated $429K sold.

Anson Funds Management first reported a position in LUMO in Q4 2018 and held it in 1 quarter. The position peaked at $429K in Q4 2018. 82 funds tracked by Wall St. Rank hold LUMO as of Q1 2019.

  • Anson Funds Management reported no remaining Lumos Pharma, Inc. Common Stock position as of Q1 2019 after selling out during the quarter.
  • Anson Funds Management sold 31,362 Lumos Pharma, Inc. Common Stock shares in Q1 2019, an estimated $429K.
  • Anson Funds Management first reported a position in Lumos Pharma, Inc. Common Stock in Q4 2018 and held it in 1 quarter.
  • Anson Funds Management's Lumos Pharma, Inc. Common Stock position peaked at $429K in Q4 2018.
  • 82 funds tracked by Wall St. Rank held Lumos Pharma, Inc. Common Stock as of Q1 2019.

Based on Anson Funds Management's 13F filing for Q1 2019, filed 15 May 2019.